Connection

GUILLERMINA LOZANO to Mutation

This is a "connection" page, showing publications GUILLERMINA LOZANO has written about Mutation.
Connection Strength

1.909
  1. Restoring p53 in cancer: the promises and the challenges. J Mol Cell Biol. 2019 07 19; 11(7):615-619.
    View in: PubMed
    Score: 0.163
  2. CRISPR/Cas9 can mediate high-efficiency off-target mutations in mice in vivo. Cell Death Dis. 2018 Oct 27; 9(11):1099.
    View in: PubMed
    Score: 0.155
  3. Somatic Trp53 mutations differentially drive breast cancer and evolution of metastases. Nat Commun. 2018 09 27; 9(1):3953.
    View in: PubMed
    Score: 0.154
  4. The Enigma of p53. Cold Spring Harb Symp Quant Biol. 2016; 81:37-40.
    View in: PubMed
    Score: 0.136
  5. Pla2g16 phospholipase mediates gain-of-function activities of mutant p53. Proc Natl Acad Sci U S A. 2014 Jul 29; 111(30):11145-50.
    View in: PubMed
    Score: 0.115
  6. The mutant p53 mouse as a pre-clinical model. Oncogene. 2013 Sep 12; 32(37):4325-30.
    View in: PubMed
    Score: 0.104
  7. You can win by losing: p53 mutations in rhabdomyosarcomas. J Pathol. 2010 Oct; 222(2):124-8.
    View in: PubMed
    Score: 0.089
  8. p53 mutation heterogeneity in cancer. Biochem Biophys Res Commun. 2005 Jun 10; 331(3):834-42.
    View in: PubMed
    Score: 0.061
  9. p53R172H and p53R245W Hotspot Mutations Drive Distinct Transcriptomes in Mouse Mammary Tumors Through a Convergent Transcriptional Mediator. Cancer Res Commun. 2024 Aug 01; 4(8):1991-2007.
    View in: PubMed
    Score: 0.058
  10. p53R245W Mutation Fuels Cancer Initiation and Metastases in NASH-driven Liver Tumorigenesis. Cancer Res Commun. 2023 12 29; 3(12):2640-2652.
    View in: PubMed
    Score: 0.056
  11. Triple-negative breast tumors are dependent on mutant p53 for growth and survival. Proc Natl Acad Sci U S A. 2023 08 22; 120(34):e2308807120.
    View in: PubMed
    Score: 0.054
  12. Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants. Cancer Res. 2023 07 14; 83(14):2297-2311.
    View in: PubMed
    Score: 0.054
  13. Is loss of p53 a driver of ductal carcinoma in situ progression? Br J Cancer. 2022 11; 127(10):1744-1754.
    View in: PubMed
    Score: 0.050
  14. Alterations of the Mdm2 C-Terminus Differentially Impact Its Function In Vivo. Cancer Res. 2022 04 01; 82(7):1313-1320.
    View in: PubMed
    Score: 0.049
  15. Men1 maintains exocrine pancreas homeostasis in response to inflammation and oncogenic stress. Proc Natl Acad Sci U S A. 2020 03 24; 117(12):6622-6629.
    View in: PubMed
    Score: 0.043
  16. Integrative genome analysis of somatic p53 mutant osteosarcomas identifies Ets2-dependent regulation of small nucleolar RNAs by mutant p53 protein. Genes Dev. 2017 09 15; 31(18):1847-1857.
    View in: PubMed
    Score: 0.036
  17. Tumorigenesis promotes Mdm4-S overexpression. Oncotarget. 2017 Apr 18; 8(16):25837-25847.
    View in: PubMed
    Score: 0.035
  18. The p53 inhibitor Mdm4 cooperates with multiple genetic lesions in tumourigenesis. J Pathol. 2017 03; 241(4):501-510.
    View in: PubMed
    Score: 0.034
  19. Attenuating the p53 Pathway in Human Cancers: Many Means to the Same End. Cold Spring Harb Perspect Med. 2016 08 01; 6(8).
    View in: PubMed
    Score: 0.033
  20. Lack of Immunomodulatory Interleukin-27 Enhances Oncogenic Properties of Mutant p53 In Vivo. Clin Cancer Res. 2016 08 01; 22(15):3876-83.
    View in: PubMed
    Score: 0.032
  21. Mutant p53 accumulates in cycling and proliferating cells in the normal tissues of p53 R172H mutant mice. Oncotarget. 2015 Jul 20; 6(20):17968-80.
    View in: PubMed
    Score: 0.031
  22. Inhibition of the mutant p53 gene in transformation assays. J Surg Res. 1992 Apr; 52(4):401-5.
    View in: PubMed
    Score: 0.025
  23. Analysis of p53 mutants for transcriptional activity. Mol Cell Biol. 1991 Dec; 11(12):6067-74.
    View in: PubMed
    Score: 0.024
  24. Multiple stress signals activate mutant p53 in vivo. Cancer Res. 2011 Dec 01; 71(23):7168-75.
    View in: PubMed
    Score: 0.024
  25. Tissue-specific expression of p53 in transgenic mice is regulated by intron sequences. Mol Carcinog. 1991; 4(1):3-9.
    View in: PubMed
    Score: 0.023
  26. Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science. 1990 Aug 31; 249(4972):1049-51.
    View in: PubMed
    Score: 0.022
  27. Targeted mutation of p53 and Rb in mesenchymal cells of the limb bud produces sarcomas in mice. Carcinogenesis. 2009 Oct; 30(10):1789-95.
    View in: PubMed
    Score: 0.020
  28. High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas. Hum Pathol. 2007 Oct; 38(10):1553-62.
    View in: PubMed
    Score: 0.018
  29. Crippling p53 activities via knock-in mutations in mouse models. Oncogene. 2007 Apr 02; 26(15):2177-84.
    View in: PubMed
    Score: 0.017
  30. New mouse models of cancer: single-cell knockouts. Proc Natl Acad Sci U S A. 2007 Mar 13; 104(11):4245-6.
    View in: PubMed
    Score: 0.017
  31. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell. 2004 Dec 17; 119(6):861-72.
    View in: PubMed
    Score: 0.015
  32. p73 gene alterations and expression in primary oral and laryngeal squamous carcinomas. Carcinogenesis. 2001 May; 22(5):729-35.
    View in: PubMed
    Score: 0.012
  33. The loss of mdm2 induces p53-mediated apoptosis. Oncogene. 2000 Mar 23; 19(13):1691-7.
    View in: PubMed
    Score: 0.011
  34. Exclusion of a p53 germline mutation in a classic Li-Fraumeni syndrome family. Hum Genet. 1998 Jun; 102(6):681-6.
    View in: PubMed
    Score: 0.009
  35. A spontaneous model of spondyloarthropathies that develops bone loss and pathological bone formation: A process regulated by IL27RA-/- and mutant-p53. PLoS One. 2018; 13(3):e0193485.
    View in: PubMed
    Score: 0.009
  36. Heterozygous p53(V172F) mutation in cisplatin-resistant human tumor cells promotes MDM4 recruitment and decreases stability and transactivity of p53. Oncogene. 2016 09 08; 35(36):4798-806.
    View in: PubMed
    Score: 0.008
  37. Characterization of a murine p53ser246 mutant equivalent to the human p53ser249 associated with hepatocellular carcinoma and aflatoxin exposure. Mol Carcinog. 1995 Jun; 13(2):104-11.
    View in: PubMed
    Score: 0.008
  38. Structural and functional analysis of p53: the acidic activation domain has transforming capability. Cell Growth Differ. 1994 Oct; 5(10):1023-31.
    View in: PubMed
    Score: 0.007
  39. Loss of the novel tumour suppressor and polarity gene Trim62 (Dear1) synergizes with oncogenic Ras in invasive lung cancer. J Pathol. 2014 Sep; 234(1):108-19.
    View in: PubMed
    Score: 0.007
  40. The p53-Mdm2 feedback loop protects against DNA damage by inhibiting p53 activity but is dispensable for p53 stability, development, and longevity. Genes Dev. 2013 Sep 01; 27(17):1857-67.
    View in: PubMed
    Score: 0.007
  41. Loss of PML cooperates with mutant p53 to drive more aggressive cancers in a gender-dependent manner. Cell Cycle. 2013 Jun 01; 12(11):1722-31.
    View in: PubMed
    Score: 0.007
  42. A functionally inactive p53 Li-Fraumeni syndrome mutant. Oncogene. 1993 Feb; 8(2):299-306.
    View in: PubMed
    Score: 0.007
  43. p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. Cancer Cell. 2012 Jun 12; 21(6):793-806.
    View in: PubMed
    Score: 0.006
  44. Mutant p53 disrupts role of ShcA protein in balancing Smad protein-dependent and -independent signaling activity of transforming growth factor-? (TGF-?). J Biol Chem. 2011 Dec 23; 286(51):44023-44034.
    View in: PubMed
    Score: 0.006
  45. An intron binding protein is required for transformation ability of p53. Nucleic Acids Res. 1991 Sep 11; 19(17):4747-52.
    View in: PubMed
    Score: 0.006
  46. p53 status in stromal fibroblasts modulates tumor growth in an SDF1-dependent manner. Cancer Res. 2010 Dec 01; 70(23):9650-8.
    View in: PubMed
    Score: 0.006
  47. Transcriptional mechanisms controlling types I and III collagen genes. Ann N Y Acad Sci. 1990; 580:88-96.
    View in: PubMed
    Score: 0.005
  48. An information-theoretic analysis of genetics, gender and age in cancer patients. PLoS One. 2008 Apr 09; 3(4):e1951.
    View in: PubMed
    Score: 0.005
  49. An inducible mouse model for skin cancer reveals distinct roles for gain- and loss-of-function p53 mutations. J Clin Invest. 2007 Jul; 117(7):1893-901.
    View in: PubMed
    Score: 0.004
  50. Loss of Gcn5 acetyltransferase activity leads to neural tube closure defects and exencephaly in mouse embryos. Mol Cell Biol. 2007 May; 27(9):3405-16.
    View in: PubMed
    Score: 0.004
  51. HDM4 (HDMX) is widely expressed in adult pre-B acute lymphoblastic leukemia and is a potential therapeutic target. Mod Pathol. 2007 Jan; 20(1):54-62.
    View in: PubMed
    Score: 0.004
  52. Li-Fraumeni syndrome: a p53 family affair. Cell Cycle. 2005 Jul; 4(7):865-7.
    View in: PubMed
    Score: 0.004
  53. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004 Nov 24; 119(5):591-602.
    View in: PubMed
    Score: 0.004
  54. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell. 2003 Mar 21; 112(6):779-91.
    View in: PubMed
    Score: 0.003
  55. Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways. Proc Natl Acad Sci U S A. 2002 Nov 12; 99(23):14849-54.
    View in: PubMed
    Score: 0.003
  56. TP53 mutation and haplotype analysis of two large African American families. Hum Mutat. 1999; 14(3):216-21.
    View in: PubMed
    Score: 0.002
  57. Isolation of the Aspergillus nidulans sudD gene and its human homologue. Gene. 1998 May 12; 211(2):323-9.
    View in: PubMed
    Score: 0.002
  58. mdm2 deletion does not alter growth characteristics of p53-deficient embryo fibroblasts. Oncogene. 1996 Oct 17; 13(8):1731-6.
    View in: PubMed
    Score: 0.002
  59. Dominance of wild-type p53-mediated transcriptional activation in breast epithelial cells. Oncogene. 1996 Sep 19; 13(6):1315-22.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.